

Jing-Quan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9255159/publications.pdf>

Version: 2024-02-01

62
papers

1,789
citations

304368

22
h-index

288905

40
g-index

63
all docs

63
docs citations

63
times ranked

1710
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018, 41, 1-25.	6.5	420
2	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2021, 54, 100743.	6.5	107
3	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. <i>Cancer Letters</i> , 2019, 440-441, 82-93.	3.2	83
4	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. <i>Drug Discovery Today</i> , 2021, 26, 1284-1292.	3.2	65
5	ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. <i>Journal of Evidence-Based Medicine</i> , 2021, 14, 232-256.	0.7	57
6	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5988-6001.	2.9	53
7	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. <i>Biochemical Pharmacology</i> , 2019, 166, 120-127.	2.0	52
8	Olmudinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1097.	1.6	47
9	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Biochemical Pharmacology</i> , 2018, 158, 274-285.	2.0	47
10	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. <i>Molecules</i> , 2019, 24, 4383.	1.7	46
11	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. <i>Frontiers in Pharmacology</i> , 2018, 9, 1236.	1.6	41
12	FRP stay-in-place form and shear key connection for FRP-concrete hybrid beams/decks. <i>Composite Structures</i> , 2018, 192, 489-499.	3.1	40
13	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. <i>Cancers</i> , 2020, 12, 466.	1.7	37
14	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Cancers</i> , 2020, 12, 186.	1.7	33
15	Bolted Shear Connection of FRP-Concrete Hybrid Beams. <i>Journal of Composites for Construction</i> , 2018, 22, .	1.7	31
16	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. <i>Future Medicinal Chemistry</i> , 2019, 11, 323-336.	1.1	31
17	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 955.	1.3	31
18	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 671788.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. <i>Frontiers in Oncology</i> , 2019, 9, 514.	1.3	29
20	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 849-862.	2.6	28
21	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. <i>Frontiers in Oncology</i> , 2020, 10, 700.	1.3	25
22	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1387.	1.8	25
23	Modulating the function of ABCB1: <i>in vitro</i> and <i>in vivo</i> characterization of sitravatinib, a tyrosine kinase inhibitor. <i>Cancer Communications</i> , 2020, 40, 285-300.	3.7	24
24	Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. <i>Cancer Science</i> , 2020, 111, 2872-2882.	1.7	24
25	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 1208.	1.6	23
26	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. <i>European Journal of Pharmacology</i> , 2019, 863, 172611.	1.7	22
27	The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide. <i>Cancers</i> , 2020, 12, 1963.	1.7	21
28	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. <i>Biochemical Pharmacology</i> , 2020, 175, 113848.	2.0	21
29	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4095.	1.8	19
30	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. <i>Cancers</i> , 2020, 12, 3249.	1.7	19
31	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. <i>Protein and Cell</i> , 2021, 12, 586-591.	4.8	18
32	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 601400.	1.8	18
33	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 674.	1.3	18
34	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 228.	1.3	15
35	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 615824.	1.6	14
36	Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 865.	1.8	13

#	ARTICLE	IF	CITATIONS
37	Dynamic characteristics analysis of partial-interaction composite continuous beams. <i>Steel and Composite Structures</i> , 2016, 21, 195-216.	1.3	13
38	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111223.	2.5	12
39	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1219.	1.3	11
40	Overexpression of ABCC1 Confers Drug Resistance to Betulin. <i>Frontiers in Oncology</i> , 2021, 11, 640656.	1.3	11
41	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. <i>Drug Discovery Today</i> , 2021, 26, 1293-1301.	3.2	11
42	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2463.	1.8	10
43	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607275.	1.8	9
44	Natural Product as Substrates of ABC Transporters: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021, 16, 222-238.	0.8	9
45	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 620874.	1.6	8
46	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697927.	1.8	8
47	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. <i>Experimental Cell Research</i> , 2021, 405, 112728.	1.2	8
48	Insights on the structure–function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. <i>MedComm</i> , 2021, 2, 221-235.	3.1	7
49	MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2609-2618.	5.7	7
50	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. <i>Frontiers in Oncology</i> , 2021, 11, 731260.	1.3	6
51	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. <i>Molecular Cancer</i> , 2022, 21, 40.	7.9	5
52	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2022, 13, 843829.	1.6	5
53	VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. <i>Cancers</i> , 2021, 13, 4675.	1.7	4
54	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. <i>International Journal of Biological Sciences</i> , 2021, 17, 2652-2665.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Therapeutic implication of carbon monoxide in drug resistant cancers. <i>Biochemical Pharmacology</i> , 2022, 201, 115061.	2.0	4
56	VSV-G Viral Envelope Glycoprotein Prepared from <i>Pichia pastoris</i> Enhances Transfection of DNA into Animal Cells. <i>Journal of Microbiology and Biotechnology</i> , 2017, 27, 1098-1105.	0.9	3
57	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7. , 2020, , .		2
58	Abstract 3796: Selonsertib, an ASK1 inhibitor, antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Cancer Research</i> , 2019, 79, 3796-3796.	0.4	1
59	Abstract 3006: Anticancer and multidrug resistance-reversing activities of novel antimicrobial peptides. , 2020, , .		1
60	Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. , 2020, , .		1
61	Paclitaxel and chemoresistance. , 2022, , 251-267.		1
62	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021, 16, 44-53.	0.8	0